Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil

(E-pub Ahead of Print)

Author(s): Neslisah BARLAK, Fatma SANLI, Ozel CAPIK, Elanur TUYSUZ, Elanur AYDIN KARATAS, Hasan TURKEZ, Omer Faruk KARATAS*.

Journal Name: Clinical Cancer Drugs

Become EABM
Become Reviewer


Background: Larynx cancer (LCa) is the most common head and neck cancer and accounts for 1-2.5% of all human cancers worldwide. Metformin, an oral anti-diabetic drug, has been recently shown to have anti-cancer activity in various cancer types and there are several studies in the literature pointing its potential to sensitize cancer cells to chemotherapeutic drugs.

Objective: In this study, we aimed at exploring the anti-cancer effects of metformin alone or in combination with 5-fluorouracil (5-FU) on Hep-2 cells.

Methods: The effects of metformin and/or 5-FU on the proliferative, clonogenic, and apoptotic potential of Hep-2 cells were evaluated with Cell Counting Kit-8, soft agar assay and Annexin V-FITC Apoptosis assay, respectively. Migratory and invasive potential of cells were tested using scratch, transwell migration and Matrigel invasion assays. Gene expression of cells exposed to metformin and/or 5-FU were profiled using RT2 mRNA PCR Array plates.

Results: Treatment of Hep-2 cells with metformin inhibited cell proliferation by inducing apoptosis, and suppressed cell migration. Besides, treatment of metformin along with 5-FU improved the anti-proliferative and anti-migratory effects of 5-FU. However, unexpectedly, metformin was found to enhance cellular invasion and reverse the inhibitory effect of 5-FU on the invasive potential of Hep-2 cells.

Conclusion: Our findings suggest that metformin might be used as an adjuvant agent in the treatment of LCa. However, the potential of metformin to promote the invasion of cancer cells should not be neglected.

Keywords: Metformin, Larynx cancer, Hep-2 Cells, 5-Fluorouracil, Chemotherapy, Adjuvant

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2212697X06666190906165309

Article Metrics

PDF: 1